Haemonetics Corporation (HAE)

Total asset turnover

		Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020
Revenue (ttm)	US$ in thousands	1,360,824	1,373,515	1,361,223	1,333,895	1,309,055	1,270,181	1,239,232	1,218,534	1,168,660	1,129,246	1,083,714	1,026,126	993,196	953,223	933,825	903,414	870,463	883,926	902,525	945,605
Total assets	US$ in thousands	2,450,950	2,531,270	2,525,220	2,540,980	2,195,590	2,200,430	2,011,280	1,962,260	1,934,820	1,878,070	1,865,110	1,820,530	1,859,730	1,831,380	1,801,500	1,794,190	1,819,920	1,318,070	1,418,170	1,433,170
Total asset turnover		0.56	0.54	0.54	0.52	0.60	0.58	0.62	0.62	0.60	0.60	0.58	0.56	0.53	0.52	0.52	0.50	0.48	0.67	0.64	0.66

March 31, 2025 calculation

Total asset turnover = Revenue (ttm) ÷ Total assets
= $1,360,824K ÷ $2,450,950K
= 0.56

Total Asset Turnover is a financial ratio that measures a company's efficiency in generating revenue from its assets. Haemonetics Corporation's Total Asset Turnover has shown some fluctuations over the past few years.

From June 30, 2020, to December 31, 2020, the ratio increased from 0.66 to 0.67, indicating an improvement in the company's ability to generate sales from its assets. However, there was a significant decrease in the ratio from March 31, 2021, to June 30, 2021, dropping from 0.48 to 0.50, suggesting a temporary decline in efficiency in asset utilization.

From September 30, 2021, to December 31, 2022, the ratio remained relatively stable, hovering around 0.52 to 0.60. This stability indicates that the company has been maintaining a consistent level of revenue generation relative to its asset base during this period.

In the most recent quarter, from March 31, 2025, the Total Asset Turnover ratio improved to 0.56, showing a positive trend in the company's efficiency in utilizing its assets to generate sales revenue.

Overall, Haemonetics Corporation's Total Asset Turnover ratio has exhibited some variability, but it appears to have stabilized and even improved in recent periods, reflecting a reasonable level of efficiency in asset utilization to drive revenue growth.